by April Breyer Menon | Aug 11, 2021
Download PDF Download...
by April Breyer Menon | Aug 10, 2021
Venable Fizpatrick partner Ha Kung Wong’s expert opinion was cited in an article about the Supreme Court’s opinion in California v. Texas, upholding the Affordable Care Act (ACA). According to Wong, it remains to be seen how future constitutional attacks,...
by April Breyer Menon | Jul 29, 2021
On July 28, 2021, the FDA approved Viatris (formerly Mylan) and Biocon Biologics’ Semglee® (insulin glargine-yfgn) as the first interchangeable biosimilar in the U.S. Semglee is both biosimilar to, and interchangeable with Sanofi’s Lantus® (insulin glargine). Based...
by April Breyer Menon | Jul 28, 2021
Venable Fizpatrick partner Ha Kung Wong spoke with Managing IP about the current rate of biologic drug post grant reviews (PGRs) at the Patent Trial and Appeal Board (PTAB) and a potential uptick in the future. He also discussed reasons PGRs may be filed instead of...
by April Breyer Menon | Jul 13, 2021
Download PDF Download...